Why Join the Registry?
Being part of the IBD Registry is one of the IBD Standards. It brings benefits in terms of quality, safety and efficiency to clinical teams and hospitals. Having better local data collected electronically helps teams to manage their IBD service more effectively. Clinicians can access shared, current information at the point of care to inform treatment decisions. Local reports facilitate audit and activity reporting, and work lists make safety monitoring and reviewing practice against standards and guidelines easy to do.
Local data can be used to support business cases for service development and negotiations with CCGs in England. The team at Luton and Dunstable University Hospital used data collected using the PMS to demonstrate the value to patients of its telephone consultations; the CCG agreed to pay for them when they avert an outpatient appointment and the savings have funded a new IBD specialist nurse. In Dorset, data provided to the CCG resulted in the IBD service helpline being funded for the first time in its 20 history.
The 2016-17 focus on key performance indicators (KPIs) for biological therapies supports better local management of biologics patients and gives clinical teams the chance to be part of a national audit of the safety and appropriate use of biologics and biosimilars, informing local and national practice.
|IBD Registry biologics KPIs 2016-17 – September 2016|
Information on the KPIs that have been selected for the ongoing biological therapies data collection through 2016/10/17
Clinicians can also use activity data for CPD, appraisal and revalidation.
Teams can participate using a choice of data entry systems to suit their local needs.
Dr Keith Bodger explains some of the benefits of joining the IBD Registry
Find out more about:
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD). The IBD hub, to be known as G.I. Know, will bring together key and separate data assets in a unified research-enabled...
The IBD Registry is inviting UK IBD clinical centres to participate in a post-marketing safety study of patients using Zessly (infliximab), a biosimilar available for the treatment of Inflammatory Bowel Disease (IBD). This study is facilitated by the Registry on...
The IBD Registry is delighted a presentation prepared by the Registry’s Analytics Hub at the University of Liverpool featured in the British Society of Gastroenterology Annual Meeting in Glasgow. The Audit of biological therapy for IBD - Shawihdi et al Poster BSG 2019...
The IBD Registry says the launch of the new IBD Standards, the first for six years, at the BSG Annual meeting in Glasgow today, Thursday, 20th June, will provide a catalyst to drive quality in inflammatory bowel disease (IBD). The IBD Standards, produced by IBD UK, an...
Continuing its mission to improve the care that people with IBD receive, the Royal College of Physicians is offering IBD teams an opportunity to participate in a new quality improvement collaborative, consisting of three 1-day learning sessions and supported action...